Conference reports

Launch of guide to the use of drug level monitoring

10th Conference on Retroviruses and Opportunistic Infections (CROI), 10-14 February 2003, Boston, USA

Pharmacokinetic papers from 10th CROI

Pediatric studies from 10th CROI

10th Conference on Retroviruses and Opportunistic Infections (CROI), 10-14 February 2003, Boston, USA

Pipeline compounds in Phase 2/3 Studies

96-week results show tenofovir-including regimen has side-effect advantages over d4T regimen in treatment naïve patients

2NN results – nevirapine and efavirenz in prospective randomised head-to-head study

NIH/NIAID study of generic drugs shows results consistent with stringent manufacturing standards

Treatment interruptions: cycles, pauses, are just plain stopping?

Conference has strong emphasis on women

Tenofovir and renal tubular dysfunction

Approaches to treatment of lipodystrophy

Surgery for buffalo hump shows variable results depending on method

Other studies – nucleosides and switching to abacavir; importance of lipoatrophy and buffalo hump

HAART to HEART: cardiovascular risk in HIV

Alendronate, vitamin D and calcium are safe and effective treatment for HIV-associated bone loss

Bone loss and fat loss are closely related in HIV patients on HAART

Low dose 200/100 IDV/RTV managed by TDM in substudy of co-infected patients

12-week response predicts which HIV-HCV coinfected patients will not benefit from continued pegylated interferon plus ribavirin

Pegylated interferon associated with eye disorders

Nevirapine resistance – the cautionary tales continue

10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003, Boston, USA

6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow, UK

Combination of three generic drugs in one pill meets bioequivalence criteria when compared with the branded drugs: Triomune vs d4T/3TC/NVP

An overview of the conference

Pharmacokinetic evaluation of tenofovir and enteric-coated ddI

The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates

Promising data regarding DermaVir for therapeutic vaccine

Enfuvirtide (T-20): predicting success and modelling survival benefits

Virologic failure among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz

Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients

Safety profile of tenofovir in treatment-experienced patients

42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, 27-30 September 2002

Immunology and treatment interruption data presented at the 42nd ICAAC

Treatment interruptions may result in poor T-cell recovery in patients with nadir CD+ count <50 cells/mm3

Treatment interruptions are safe in patients with CD4+ count between 300 to 500 cells/mm3 and viral loads lower than 70,000 copies/mL

Topical transdermal testosterone gel offers significant clinical benefits in hypogonadal HIV-positive patients

BMS experimental PI atazanavir shows potency comparable to NNRTI efavirenz among treatment-naïve HIV patients

Adverse drug reactions and lipodystrophy in children

Study suggests Kaletra/Combivir is better tolerated PEP than Combivir/nelfinavir

Novel approaches to the inhibition of HIV

Lipodystrophy and adverse drug reaction data presented at the 42nd ICAAC

4th International Workshop on Drug Reactions and Lipodystrophy in HIV Infection, San Diego, 22-25 September 2002

Leptin, lipodystrophy and insulin resistance

A range of treatments for facial lipoatrophy

Autopsy evidence confirms that ARVs tackle CNS lesions

XI International HIV Drug Resistance Workshop, Seville, 2-5 July, 2002

Short resistance reports from Seville

New anti-HIV compounds discussed at the Seville HIV Drug Resistance Workshop and the Barcelona World AIDS Conference

Review of phenotypic resistance testing data presented at the XI International HIV Drug Resistance Workshop

XIV International AIDS Conference Barcelona, 7-12 July 2002

Bill Clinton and Nelson Mandela promise to lead peer education among political leaders as world looks for $10 billion a year to fight HIV/AIDS

South African activist unveils campaign to force compulsory licences

MSF study shows treatment in resource-poor settings is effective

‘Barcelona Declaration’ demands 2m poor people are treated in the next two years

Lives were lost as experts argued the merits of care versus prevention, says Stefano Vella

Peter Piot sets out the global political agenda in the fight against HIV/AIDS

Health should be a right, not a commodity, and medicine must be removed from the World Trade Organisation, argues key speaker

Governments must act to cut drug prices, says Kenya’s health minister

Civil society had to fight for universal access to AIDS drugs in Brazil

Coalitions of local NGOs can effectively demand access to medicines, reports MSF

Involvement of PLWHA is key to improving access to treatments

ART can successfully tackle advanced disease in resource poor settings, reports MSF

Investment in treatment and care significantly reduces company health and social expenditure in Abidjan

Post navigation